Citation APA
Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clement, C., Dijoud, F., Rigau, V., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Miron, J., Jeziorski, E., Plat, G., Aladjidi, N., Ferster, A., Pacquement, H., Galambrun, C., Brugières, L., Leverger, G., Mansuy, L., Paillard, C., Deville, A., Armari-Alla, C., Lutun, A., Gillibert-Yvert, M., Stephan, J. L., Cohen-Aubart, F., Haroche, J., Pellier, I., Millot, F., Lescoeur, B., Gandemer, V., Bodemer, C., Lacave, R., Hélias-Rodzewicz, Z., Taly, V., Geissmann, F., & Donadieu, J. (2016). BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of clinical oncology, 34(25), 3023-3030. doi:10.1200/JCO.2015.65.9508
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/264797